Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)-GH23-003, Conducting Public Health Research With Universities in Thailand; Amended Notice of Closed Meeting, 16014 [2023-05297]
Download as PDF
16014
Federal Register / Vol. 88, No. 50 / Wednesday, March 15, 2023 / Notices
Dated: March 9, 2023.
Terrance Perry,
Chief Grants Management Officer, Centers for
Disease Control and Prevention.
[FR Doc. 2023–05256 Filed 3–14–23; 8:45 am]
BILLING CODE 4163–18–P
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2023–05297 Filed 3–14–23; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP)—GH23–003,
Conducting Public Health Research
With Universities in Thailand;
Amended Notice of Closed Meeting
Clinical Laboratory Improvement
Advisory Committee
Notice is hereby given of a change in
the meeting of the Disease, Disability,
and Injury Prevention and Control
Special Emphasis Panel (SEP)—GH23–
003, Conducting Public Health Research
with Universities in Thailand; April 12,
2023, 9 a.m.–2:30 p.m., EDT,
teleconference, in the original Federal
Register Notice. The meeting was
published in the Federal Register on
March 2, 2023, Volume 88, Number 41,
page 13121.
The meeting is being amended to add
a Notice of Funding Opportunity
number and should read as follows:
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
GH20–002, Malaria Operations
Research to Improve Malaria Control
and Reduce Morbidity and Mortality in
Western Kenya; and GH23–003,
Conducting Public Health Research with
Universities in Thailand.
The meeting is closed to the public.
lotter on DSK11XQN23PROD with NOTICES1
FOR FURTHER INFORMATION CONTACT:
Hylan Shoob, Ph.D., Scientific Review
Officer, Center for Global Health, CDC,
1600 Clifton Road NE, Mailstop H21–9,
Atlanta, Georgia 30329–4027;
Telephone: (404) 639–4796; Email:
HShoob@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
VerDate Sep<11>2014
18:48 Mar 14, 2023
Jkt 259001
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
In accordance with regulatory
provisions, the Centers for Disease
Control and Prevention (CDC)
announces the following meeting for the
Clinical Laboratory Improvement
Advisory Committee (CLIAC). This
meeting is open to the public, limited
only by the number of webcast lines
available. Time will be available for
public comment.
DATES: The meeting will be held on
April 12, 2023, from 11 a.m. to 5:30
p.m., EDT, and April 13, 2023, from 11
a.m. to 5 p.m., EDT.
ADDRESSES: This is a virtual meeting.
Meeting times are tentative and subject
to change. The confirmed meeting
times, agenda items, and meeting
materials, including instructions for
accessing the live meeting broadcast,
will be available on the CLIAC website
at https://www.cdc.gov/cliac. Check the
website on the day of the meeting for
the web conference link.
FOR FURTHER INFORMATION CONTACT:
Heather Stang, MS, Senior Advisor for
Clinical Laboratories, Division of
Laboratory Systems, Office of
Laboratory Science and Safety, Centers
for Disease Control and Prevention,
1600 Clifton Road NE, Mailstop V24–3,
Atlanta, Georgia 30329–4027.
Telephone: (404) 498–2769; Email:
HStang@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: The Clinical Laboratory
Improvement Advisory Committee
(CLIAC) is charged with providing
scientific and technical advice and
guidance to the Secretary, HHS; the
Assistant Secretary for Health; the
Director, CDC; the Commissioner, Food
and Drug Administration (FDA); and the
Administrator, Centers for Medicare &
SUMMARY:
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
Medicaid Services (CMS). The advice
and guidance pertain to general issues
related to improvement in clinical
laboratory quality and laboratory
medicine and specific questions related
to possible revision of the Clinical
Laboratory Improvement Amendments
of 1988 (CLIA) standards. Examples
include providing guidance on studies
designed to improve quality, safety,
effectiveness, efficiency, timeliness,
equity, and patient-centeredness of
laboratory services; revisions to the
standards under which clinical
laboratories are regulated; the impact of
proposed revisions to the standards on
medical and laboratory practice; and the
modification of the standards and
provision of non-regulatory guidelines
to accommodate technological
advances, such as new test methods, the
electronic transmission of laboratory
information, and mechanisms to
improve the integration of public health
and clinical laboratory practices.
Matters To Be Considered: The agenda
will include agency updates from CDC,
CMS, and FDA. Presentations and
CLIAC discussions will focus on reports
from two CLIAC workgroups: the CLIA
Regulations Assessment Workgroup and
the CLIA Certificate of Waiver and
Certificate for Provider-performed
Microscopy Procedures Workgroup, and
on the laboratory’s role in advancing
health equity. Agenda items are subject
to change as priorities dictate.
Public Participation
It is the policy of CLIAC to accept
written public comments and provide a
brief period for oral public comments
pertinent to agenda items.
Oral Public Comment: Public
comment periods for each agenda item
are scheduled immediately prior to the
Committee discussion period for that
item. In general, each individual or
group requesting to present an oral
comment will be limited to a total time
of five minutes (unless otherwise
indicated). Speakers should email
CLIAC@cdc.gov or notify the contact
person above (see FOR FURTHER
INFORMATION CONTACT) at least five
business days prior to the meeting date.
Written Public Comment: CLIAC
accepts written comments until the date
of the meeting (unless otherwise stated).
However, it is requested that comments
be submitted at least five business days
prior to the meeting date so that the
comments may be made available to the
Committee for their consideration and
public distribution. Written comments
should be submitted by email to
CLIAC@cdc.gov or to the contact person
above. All written comments will be
E:\FR\FM\15MRN1.SGM
15MRN1
Agencies
[Federal Register Volume 88, Number 50 (Wednesday, March 15, 2023)]
[Notices]
[Page 16014]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-05297]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel (SEP)--GH23-003, Conducting Public Health Research With
Universities in Thailand; Amended Notice of Closed Meeting
Notice is hereby given of a change in the meeting of the Disease,
Disability, and Injury Prevention and Control Special Emphasis Panel
(SEP)--GH23-003, Conducting Public Health Research with Universities in
Thailand; April 12, 2023, 9 a.m.-2:30 p.m., EDT, teleconference, in the
original Federal Register Notice. The meeting was published in the
Federal Register on March 2, 2023, Volume 88, Number 41, page 13121.
The meeting is being amended to add a Notice of Funding Opportunity
number and should read as follows:
Name of Committee: Disease, Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)-- GH20-002, Malaria Operations
Research to Improve Malaria Control and Reduce Morbidity and Mortality
in Western Kenya; and GH23-003, Conducting Public Health Research with
Universities in Thailand.
The meeting is closed to the public.
FOR FURTHER INFORMATION CONTACT: Hylan Shoob, Ph.D., Scientific Review
Officer, Center for Global Health, CDC, 1600 Clifton Road NE, Mailstop
H21-9, Atlanta, Georgia 30329-4027; Telephone: (404) 639-4796; Email:
[email protected].
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2023-05297 Filed 3-14-23; 8:45 am]
BILLING CODE 4163-18-P